Study offers fresh insight into racial disparities in prostate cancer May 20, 2021 Among patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving abiraterone acetate (Zytiga) plus prednisone, survival outcomes were similar between Black and White men, while Black men trended toward higher declines in PSA and time to PSA progression (TTP), according to outcomes from a race-stratified prospective study.1,2Several other key findings emerged from the trial, including higher treatment toxicity in Black men and the identification of a potential biomarker of ancestry‐dependent treatment outcomes.Read the full article here. Source: Jason M. Broderick - Urology Times Prostate Cancer News
Among patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving abiraterone acetate (Zytiga) plus prednisone, survival outcomes were similar between Black and White men, while Black men trended toward higher declines in PSA and time to PSA progression (TTP), according to outcomes from a race-stratified prospective study.1,2Several other key findings emerged from the trial, including higher treatment toxicity in Black men and the identification of a potential biomarker of ancestry‐dependent treatment outcomes.Read the full article here. Source: Jason M. Broderick - Urology Times
